Following the "2023 Bone Marrow Transplantation Summer Conference" held last year, Taiwan Society of Blood and Marrow Transplantation (TBMT) hold the "Taiwan HSCT & Cell Therapy Congress 2024" on July 13, 2024. The Hematology Society of Taiwan was invited to co-sponsor the event this year.
To enhance cooperation between Taiwan and other countries in the Asia-Pacific region, many prominent foreign guests were invited to participate in this event. Additionally, to promote coloration with the industry, a dialogue focus on CAR T therapy between industry, government, and academia was specially arranged.
Notable guests included Chung-Liang Shih (石崇良), Director General of National Health Insurance Administration of the Ministry of Health and Welfare; Shin-Hun Juang (莊聲宏), Director General of the Taiwan Food and Drug Administration (TFDA); Chi-Cheng Li (李啟誠), Director General of TBMT; Bor-Sheng Ko (柯博升), Executive Director of TBMT; Shih-Peng Yeh (葉士芃), Executive Director of TBMT; Yao Ming (姚明), Executive Supervisor of TBMT; Chia-Ning Shen (沈家寧), Executive Director of Formosa Association Regenerative Medicine; Professor Kuan-Der Lee (李冠德) and representatives from many cell therapy companies in Taiwan including Caarlogic Biomed (卡洛生物醫藥), GenomeFrontier Therapeutics(先驅生技), UWELL Biopharma (宇越生醫), PELL Bio-Med Technology (沛爾生醫), ARCE Therapeutics (承寶生技), Retain Biotech (睿田生技) and LOCUS CELL (樂迦再生科技).
Our Chief Operating Officer, Karen Wen attended this conference on behalf of the company to jointly promote the advancement and commercialization of CAR-T cell therapy technology, bring better treatment options to patients, and improve patient well-being.
